Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;21(1):63-71.
doi: 10.1038/s41556-018-0205-1. Epub 2019 Jan 2.

mTOR as a central hub of nutrient signalling and cell growth

Joungmok Kim  1 , Kun-Liang Guan  2
Affiliations
Review

mTOR as a central hub of nutrient signalling and cell growth

Joungmok Kim et al. Nat Cell Biol. 2019 Jan.

Abstract

The highly conserved protein kinase mechanistic target of rapamycin (mTOR; originally known as mammalian target of rapamycin) is a central cell growth regulator connecting cellular metabolism and growth with a wide range of environmental inputs as part of mTOR complex 1 (mTORC1) and mTORC2. In this Review, we introduce the landmark discoveries in the mTOR field, starting from the isolation of rapamycin to the molecular characterizations of key components of the mTORC signalling network with an emphasis on amino acid sensing, and discuss the perspectives of mTORC inhibitors in therapeutic applications.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sabatini, D. M. Twenty-five years of mTOR: uncovering the link from nutrients to growth. Proc. Natl Acad. Sci. USA 114, 11818–11825 (2017). - PubMed
    1. Vezina, C., Kudelski, A. & Sehgal, S. N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28, 721–726 (1975). - PubMed
    1. Baker, H., Sidorowicz, A., Sehgal, S. N. & Vezina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J. Antibiot. 31, 539–545 (1978). - PubMed
    1. Douros, J. & Suffness, M. New antitumor substances of natural origin. Cancer Treat. Rev. 8, 63–87 (1981). - PubMed
    1. Eng, C. P., Sehgal, S. N. & Vezina, C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. 37, 1231–1237 (1984). - PubMed

Publication types

LinkOut - more resources